Joyce A. O'Shaughnessy, MD

Joyce A. O'Shaughnessy, MD, is co-chair of Breast Cancer Research and chair of Breast Cancer Prevention Research at Baylor Charles A. Sammons Cancer Center

Articles

Dr O’Shaughnessy on Highly Anticipated Breast Cancer Data to Watch at ESMO 2025

October 16th 2025

Joyce A. O’Shaughnessy, MD, highlights the breast cancer data being presented at ESMO 2025 that have the greatest potential to shape clinical practice.

Dr O’Shaughnessy on the Utility of the MammaPrint Assay in HR+ Breast Cancer

September 5th 2025

Joyce O’Shaughnessy, MD, discussed data that support the use of the MammaPrint assay in predicting chemotherapy benefit in HR-positive breast cancer.

Unmet Needs and Future Direction in HER2+ Breast Cancer

July 29th 2024

The panel looks to the future landscape for HER2+ breast cancer, highlighting emerging treatment practices and currently unmet needs.

Clinical Considerations and Subsequent Therapies or Sequencing in HER2-Low/HER2+ mBC

July 29th 2024

Focusing on the selection of subsequent therapies for patients with HER2-low/HER2+ metastatic breast cancer, the panel discusses treatment sequencing considerations and practices.

Clinical Perspectives on Managing ILD Related to T-DXd

July 22nd 2024

Breast cancer specialists discuss adverse events associated with T-DXd, focusing on monitoring for interstitial lung disease (ILD) and the role of re-challenging patients with T-DXd after resolution of grade 1 ILD.

Overview of DESTINY-Breast06

July 22nd 2024

Aditya Bardia, MD, MPH, shares comprehensive insights on the DESTINY-Breast06 study evaluating T-DXd in HER2-low and HER2 ultra-low metastatic breast cancer, and the panel offers its initial impressions.

Defining HER2 Low and HER2 Ultra-Low: Diagnostic Challenges

July 15th 2024

Ian Krop, MD, PhD, provides an overview of HER2-low and HER2 ultra-low breast cancer and discusses challenges encountered during diagnosis.

Impact of DESTINY-Breast09 and Other Trials on Clinical Practice and Patient Subsets

July 15th 2024

Experts on breast cancer discuss the potential impact of ongoing research in HER2+ breast cancer, highlighting how results from the DESTINY-Breast07 study may translate to DESTINY-Breast09.

Investigational Agents, Clinical Trials for Advanced HER2+ Breast Cancer

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss novel agents in the pipeline for patients with advanced HER2-positive breast cancer.

Frequent AEs and Management Approaches for Advanced HER2+ Breast Cancer

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss commonly reported adverse effects from HER2-positive breast cancer treatment and appropriate management strategies for them.

Treatment Decisions in Advanced HER2+ Breast Cancer With CNS Metastases

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss how to decide on treatment for patients with advanced or metastatic HER2-positive breast cancer who have central nervous system metastases.

Optimal Management Strategies in Advanced HER2+ Breast Cancer

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss the various management strategies for treatment of patients with advanced or metastatic HER2-positive breast cancer.

Current Prognosis for Advanced or Metastatic HER2+ Breast Cancer

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss the prognosis for patients with advanced or metastatic HER2-positive breast cancer.

Ongoing Clinical Trials in HER2+ Metastatic Breast Cancer

July 8th 2024

Melinda Telli, MD, provides an overview of ongoing research in HER2+ metastatic breast cancer, highlighting the DESTINY-Breast09, PATINA, INAVO122, and HER2CLIMB-05 studies.

Standard-of-Care Regimens for First-Line Treatment of HER2+ mBC

July 8th 2024

The panel provides comprehensive insights on approaching first-line treatment of patients with HER2+ metastatic breast cancer and the role of neratinib.

Dr O’Shaughnessy on Real-World Data for Tucatinib-Based Therapy in HER2+ Breast Cancer

April 11th 2023

Joyce A. O’Shaughnessy, MD, discusses real-world data for the use of the phase 2 HER2CLIMB trial regimen of tucatinib plus trastuzumab and capecitabine in HER2-positive breast cancer.

Dr. O’Shaughnessy on DESTINY-Breast02 and DESTINY-Breast03 in Metastatic HER2+ Breast Cancer

January 20th 2023

Joyce A. O’Shaughnessy, MD, discusses key data from the phase 3 DESTINY-Breast02 and DESTINY-Breast03 trials in metastatic HER2-positive breast cancer.

Dr. O’Shaughnessy on Pembrolizumab in Triple-Negative Breast Cancer

August 23rd 2022

Joyce A. O’Shaughnessy, MD, discusses the sequencing of pembrolizumab with chemotherapy in patients with early-stage triple-negative breast cancer.

Optimizing Treatment Strategies in Breast Cancer: Q&A

June 8th 2022

Fielding questions from their live audience, Joyce O'Shaughnessy, MD, and Sara Hurvitz, MD, discuss optimal selection of therapy for patients with breast cancer.

Clinical Trials in HER2+ mBC: DESTINY-Breast03 and HER2CLIMB

June 8th 2022

Highlights of the results from the DESTINY-Breast03 and HER2CLIMB trials, evaluating T-DXd and tucatinib, respectively, in HER2+ metastatic breast cancer.